Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,509 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 0.9% saline Clear all
Not yet recruiting Not applicable Interventional

Prevention of Oral Mucositis in Adults in With Hematologic Malignancy

NCT07809984
View directory record Official record
Conditions
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Oral Mucositis
Interventions
Aloe Vera Mouthwash, Standard of Care
Dietary Supplement · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Oak Lawn, Illinois • Park Ridge, Illinois • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 13, 2026, 4:42 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )

NCT07526974
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9% Sodium Chloride
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
11
States / cities
Encinitas, California • Aventura, Florida • Alpharetta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 13, 2026, 4:42 PM EDT
Completed Phase 4 Interventional Results available

Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis

NCT01482091
View directory record Official record
Conditions
Anemia, Sickle Cell, Pain
Interventions
Fentanyl Citrate, Normal Saline
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
3 Years to 21 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Sep 13, 2026, 4:42 PM EDT
Terminated Phase 2 Interventional

A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant

NCT01403389
View directory record Official record
Conditions
Delayed Function of Renal Transplant
Interventions
Eculizumab, Placebo
Drug
Lead sponsor
Schroppel, Bernd, M.D.
Individual
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2019 · Synced Sep 13, 2026, 4:42 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

NCT01821274
View directory record Official record
Conditions
Skin Irritation
Interventions
Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution o sodium lauryl sulfate (SLS), Saline 0.9%
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Sep 13, 2026, 4:42 PM EDT
Recruiting Phase 3 Interventional

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT07052903
View directory record Official record
Conditions
Transthyretin Amyloidosis With Cardiomyopathy
Interventions
Nucresiran, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
42
States / cities
La Jolla, California • Laguna Hills, California • Stanford, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 13, 2026, 4:42 PM EDT
Completed Not applicable Interventional Results available

Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty?

NCT02276495
View directory record Official record
Conditions
Pain Management
Interventions
ACB Control - 20 ml saline injection for ACB, ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block, Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
Other · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 13, 2026, 4:42 PM EDT
Recruiting Phase 3 Interventional

Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor

NCT05834777
View directory record Official record
Conditions
Intradialytic Hypotension
Interventions
Icatibant, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 13, 2026, 4:42 PM EDT
Recruiting Phase 1 Interventional

HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors

NCT05861895
View directory record Official record
Conditions
Solid Tumors, Adult
Interventions
HF158K1 / 1.4 g lipid dose, HF158K1 / 2.2 g lipid dose, HF158K1 / 2.9 g lipid dose
Drug
Lead sponsor
HighField Biopharmaceuticals Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 13, 2026, 4:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects

NCT00690170
View directory record Official record
Conditions
Healthy Subjects
Interventions
Ketamine, Nicotine, Placebo, Ketamine and Nicotine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 8, 2012 · Synced Sep 13, 2026, 4:42 PM EDT
Terminated Phase 2 Interventional Results available

A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD

NCT00457951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Open-Label, Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride, ODSH
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Orange, California • Marietta, Georgia • Shreveport, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 13, 2026, 4:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers

NCT01984983
View directory record Official record
Conditions
Venezuelan Equine Encephalitis Virus Infection
Interventions
Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate, 0.9% saline placebo
Biological · Other
Lead sponsor
Ichor Medical Systems Incorporated
Industry
Eligibility
18 Years to 49 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 13, 2026, 4:42 PM EDT
Withdrawn Phase 4 Interventional

Manuka Eye Droops for Treatment of Allergy

NCT03862053
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Manuka honey
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Germantown, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 13, 2026, 4:42 PM EDT
Completed Phase 3 Interventional

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

NCT00518895
View directory record Official record
Conditions
Melanoma
Interventions
dacarbazine plus Genasense, dacarbazine plus placebo
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
Mobile, Alabama • Encinitas, California • Santa Rosa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Sep 13, 2026, 4:42 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

NCT07675629
View directory record Official record
Conditions
HIV Prevention
Interventions
PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 55 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 13, 2026, 4:42 PM EDT
Terminated Phase 4 Interventional Results available

Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Exposure

NCT02899156
View directory record Official record
Conditions
Hypoactive Delirium
Interventions
Flumazenil, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Sep 13, 2026, 4:42 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of wSp Vaccine in Young Children

NCT07216430
View directory record Official record
Conditions
Acute Otitis Media (AOM)
Interventions
wSp vaccine, Saline (0.9% NaCl)
Biological
Lead sponsor
Serum Life Science Europe GmbH
Industry
Eligibility
5 Months to 7 Months
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
7
States / cities
Pittsford, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 13, 2026, 4:42 PM EDT
Withdrawn Phase 2 Interventional

REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

NCT00715364
View directory record Official record
Conditions
Stroke
Interventions
NTx™-265: rhCG, then rEPO, Saline Placebo
Drug
Lead sponsor
Stem Cell Therapeutics Corp.
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Newport Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2011 · Synced Sep 13, 2026, 4:42 PM EDT
Completed Not applicable Interventional

Saline Hypertonic in Preschoolers

NCT02378467
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
7% Hypertonic Saline (HS), 0.9% Isotonic Saline (IS)
Drug
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
3 Years to 5 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 13, 2026, 4:42 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of Rezafungin

NCT04117607
View directory record Official record
Conditions
Fungal Infection
Interventions
Placebo, Rezafungin
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 13, 2026, 4:42 PM EDT
Recruiting Phase 2Phase 3 Interventional

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

NCT06947928
View directory record Official record
Conditions
Advanced Or Metastatic Merkel Cell Carcinoma
Interventions
IFx-Hu2.0, Placebo, Pembrolizumab
Drug
Lead sponsor
TuHURA Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 13, 2026, 4:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Combining Placing a Synera Patch With Propofol/Lidocaine Mixture to Decrease Pain With IV Propofol Injection

NCT02240628
View directory record Official record
Conditions
Pain on IV Injection of Propofol.
Interventions
Lidocaine/tetracaine transdermal patch, Saline, Lidocaine
Device · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
6 Years to 17 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Sep 13, 2026, 4:42 PM EDT
Recruiting Phase 2 Interventional

Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites

NCT06812390
View directory record Official record
Conditions
Cirrhosis, Ascites Hepatic
Interventions
Albumin infusion (25% albumin), Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Anahita Rabiee MD MHS
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 13, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial

NCT00059332
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
Magnesium Sulfate, Normal Saline
Drug
Lead sponsor
Jeffrey L. Saver
Other
Eligibility
40 Years to 95 Years
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Sep 13, 2026, 4:42 PM EDT